Success Stories: Decoding the Tumor Microenvironment: A Researcher’s Impact on Pancreatic Cancer Science

Client’s Testimonial:

“Thank you for reaching out and for the team’s unwavering support throughout the process.”

On March 8^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Research Assistant in the Field of Cancer Biology (Approval Notice).

General Field: Cancer Biology

Position at the Time of Case Filing: Senior Research Assistant

Country of Origin: Malaysia

State of Residence at the Time of Filing: New York

Approval Notice Date: March 8^th, 2025

Processing Time: 5 days (Premium Processing Requested)

Case Summary:

Among the many pressing medical challenges of our time, few are as complex and stubborn as pancreatic ductal adenocarcinoma (PDAC)—a cancer known not just for its lethality but for its ability to resist treatment and defy early detection. One Malaysian-born researcher is changing that.

Recently approved for the EB-2 National Interest Waiver (NIW) with the assistance of NAILG, this Senior Research Assistant is contributing transformational insights into the tumor microenvironment, helping chart new paths for effective cancer therapeutics.

The Science Behind the Signature

Specializing in cancer biology, the client’s proposed endeavor is sharply focused: uncovering molecular and intercellular vulnerabilities in malignant tumors to combat treatment resistance, metastasis, and immune evasion. Her work concentrates on PDAC progression—examining the ways tumor and stromal cells interact, communicate, and co-evolve.

Through techniques such as genome editing, transcriptomic profiling, and in vivo modeling, she identifies and tests therapeutic targets that could radically shift how pancreatic cancer is treated. In particular, her research on autotaxin (ATX) and its downstream effects on immune suppression in tumors offers hope for smarter and more precise interventions.

Quantifying Impact

Publications: 5 peer-reviewed articles and 1 preprint
Citation Count: 532 citations (Google Scholar)
Review Work: Her studies are cited across premier journals and referenced in global research
Funding: Projects supported by top-tier institutions including the National Cancer Institute, the S. Department of Defense, the NIH, and Cancer Research UK

These achievements are rare at her career stage and provide strong evidence that she is not only well-positioned to advance her work, but is already driving major advances in cancer biology.

From Bench to National Interest

The value of her contributions is underscored in a recommendation from a leading cancer biologist at the University of Cambridge, who wrote:

“Thanks to [client’s] exceptional expertise in pancreatic cancer research, she has become an irreplaceable asset to the scientific community. Given the tremendous challenges posed by pancreatic cancer, her work is critical for advancing our understanding of the disease and developing novel therapeutic strategies. I strongly believe that it is in the national interest of the United States to support her continued research in this critical area.”

The case made clear that the client’s work addressed critical gaps in therapeutic understanding and had already influenced clinical strategies and policy-relevant research directions.

Rapid Approval and Clear Merit

Filed under premium processing on March 3, 2025, her EB-2 NIW was approved in under a week—by March 8, 2025—a testament not only to her professional strength, but to a well-structured petition highlighting national benefit.

NAILG’s legal team framed her case around the Dhanasar criteria, demonstrating:

The substantial merit of her research
It has clear national importance, particularly for U.S. public health outcomes
Her strong positioning to advance this work is given by her skills, funding history, and scholarly recognition

From uncovering how tumor stroma fuels cancer growth to identifying immune pathways that can be reactivated, her contributions are reshaping the future of PDAC treatment. This approval reflects not only her scientific merit but also a broader national recognition of the importance of cancer-focused molecular research. NAILG is honored to have played a role in advancing her journey.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.